Ibutamoren (MK-677): what does the evidence show?

Is MK-677 a peptide or a SARM?

Ibutamoren is a small molecule that activates the ghrelin receptor, a signalling target involved in hunger and growth-hormone release. It is sometimes marketed alongside peptides and selective androgen receptor modulators (SARMs), but it is neither a peptide nor a SARM. A shared marketing category does not imply the same mechanism or evidence. Compare ipamorelin and the CJC-1295 and ipamorelin evidence.

For a related question, compare ipamorelin and MK-677: shared signals and different evidence.24

Why is ibutamoren also called LUM-201?

LUM-201 is a name used for an investigational ibutamoren product in studies of children with diagnosed growth-hormone deficiency. That research asks a different question from using MK-677 for adult muscle gain or healthy children’s growth. A trial record or a product being studied does not establish approval.

In a completed, open-label (not blinded), sponsor-run phase 2 study, ClinicalTrials.gov reports 104 children enrolled and compares several LUM-201 groups with an approved growth-hormone medicine. For the six-month height-response analysis, results were reported for 80 children who met the study’s analysis criteria: 44%, 73% and 73% across the three LUM-201 groups met the study’s predefined growth threshold, compared with 100% in the growth-hormone group. The respective groups in this analysis had 18, 22, 22 and 18 children. These are short-term study measures in selected children, not predictions of final adult height or proof of equivalent treatments.

The registry results were submitted by the sponsor, Lumos Pharma; the record alone is not an independent appraisal of the full study or long-term safety. This research does not make an online or undeclared MK-677 product appropriate for a child. Growth concerns should be assessed by a qualified paediatric clinician.10

Does a change in lean mass mean stronger muscles?

In a 2008 randomized trial, 71 healthy adults aged 60–81 were assigned ibutamoren or placebo; 65 completed the first year. Fat-free mass increased by an average of 1.1 kg in the ibutamoren group and decreased by 0.5 kg in the placebo group. Fat-free mass includes water and is not the same as new muscle tissue. The researchers did not establish improvements in measured strength or physical function; the study was too small to assess those outcomes precisely. It also found no significant difference in abdominal visceral fat.

These results do not show what happens in younger athletes or establish an anti-ageing benefit. Merck supplied the study drug and placebo; the paper reports public and other research support. A hormonal change is a biological result, not automatically a lasting functional benefit.1

Does raising IGF-1 slow Alzheimer’s disease?

A biological rationale does not establish a clinical benefit. In a 2008 double-blind trial, adults with mild-to-moderate Alzheimer’s disease were assigned ibutamoren or placebo for a year. The published report says 563 people were randomized and 416 completed treatment and assessments at 12 months. Although blood IGF-1 increased in the ibutamoren group, the researchers found no statistically significant differences in the measured changes in cognition, everyday functioning or overall clinical assessments.

A related ClinicalTrials.gov record lists Merck as sponsor and reports an actual enrollment of 512. The reason this differs from the 563 randomized in the publication is not clear from the records checked, including whether the counts cover exactly the same population. The result concerns the particular trial and population; it does not establish whether the compound prevents Alzheimer’s disease in healthy people or benefits other conditions. The abstract alone does not give enough detail to assess all adverse effects or the impact of missing outcomes. Memory changes deserve assessment by a qualified clinician.89

What risks were observed?

In the older-adult trial, fasting glucose rose on average and insulin sensitivity fell with ibutamoren. Increased appetite, fluid retention and muscle pain were also reported. These results do not predict an individual response.

Separately, FDA’s 2024 briefing describes a trial in older people after hip fracture that stopped early after more heart-failure events in the ibutamoren group: four of 62 versus one of 61 with placebo. This small, medically vulnerable population is not interchangeable with healthy users; the observation is a safety signal, not a precise risk estimate for every setting.

The published report also found a difference favouring ibutamoren on one walking-speed score, while most other functional measures did not improve. The early-stopped study and its mixed outcomes cannot establish overall rehabilitation benefit or a causal explanation for individual heart-failure events.126

Approval, products and sport

In a 2025 warning about a particular children’s product containing undisclosed ibutamoren, the US FDA said ibutamoren was not FDA approved and warned about appetite, fluid retention, glucose changes and possible heart-failure risk in some people. The finding concerns that tested product, not every product on the market. The FDA has also concluded that ibutamoren is excluded from the US dietary supplement definition. Regulatory status can differ elsewhere.

The FDA also identifies ibutamoren mesylate on its list of bulk substances nominated for compounding that may present significant safety risks, citing the hip-fracture trial. This is a US regulator safety assessment, not a clinical approval or an estimate of risk for a particular person.

The US Anti-Doping Agency lists ibutamoren as prohibited in tested sport. Product labels and “research use” claims do not establish identity, quality or safety. For the broader rules, see peptides and anti-doping. This page does not recommend use or provide sourcing or dosing instructions.3457